TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
OXFORD, UNITED KINGDOM, Aug. 03, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
-END-
For more information, please contact: Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880 N+1 Singer (Broker) Aubrey Powell / Lauren Kettle Tel: +44 (0)20 7496 3000 MacDougall Biomedical Communications (US media contact) Tel: +1 781 235 3060 Karen Sharma [email protected] Consilium Strategic Communications (Financial public relations, UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / [email protected] Jessica Hodgson / Lindsey Neville
